AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 273.9 USD | -0.88% |
|
+0.15% | -4.89% |
| 04-30 | Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla... |  |
| 04-30 | Sector Update: Health Care Stocks Mixed Premarket Tuesday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
01/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
276.4
USD
Average target price
303.3
USD
Spread / Average Target
+9.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.89% | 148B | |
| +34.00% | 664B | |
| +29.29% | 567B | |
| -7.75% | 354B | |
| +18.53% | 330B | |
| +4.95% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -11.01% | 145B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen : Oppenheimer Adjusts Amgen's Price Target to $266 From $274, Maintains Outperform Rating
